Nuwellis Receives Notice Of Allowance For New Patent Covering Advanced Safety Mechanisms For Blood Return Line Clamps Used In Extracorporeal Blood Filtration Systems, Including Vivian Pediatric CRRT System

Nuwellis, Inc. (NASDAQ:NUWE), a medical technology company committed to delivering solutions for patients with cardio-renal conditions, addressing the critical interplay between the heart and kidneys, today announced that the United States Patent and Trademark Office has issued Nuwellis a notice of allowance for a new patent covering advanced safety mechanisms for blood return line clamps used in extracorporeal blood filtration systems, including the company's Vivian™ Pediatric Continuous Renal Replacement Therapy (CRRT) System currently in development.

Many extracorporeal blood filtration systems rely on automated clamps as part of their safety design to prevent air embolism or pressure imbalances. The newly patented technology enhances this core function by dynamically adjusting clamping force based on environmental factors, automatically reconditioning the tubing under defined thermal conditions, and adding thermal insulation for improved material stability. Together, these innovations strengthen one of the most critical safety components in pediatric extracorporeal therapy—ensuring consistent, reliable protection for the smallest patients.

This patent adds to a growing portfolio of intellectual property supporting the Vivian system and Nuwellis' pediatric technology roadmap, following the September 2025 patent issuance for hemolysis sensing in extracorporeal circuits. Together, these advancements reflect meaningful progress toward safer, smarter, and more responsive pediatric fluid management.

The company's innovation in this space is further supported by National Institute of Health (NIH) grant-funded research and the use of the Aquadex® system in pediatric patients weighing 20 kg or more, helping to inform design decisions and guide future clinical applications for Vivian.

With each patent, Nuwellis continues to strengthen its leadership in precision fluid management and its mission to deliver safer, smarter solutions for patients across the cardio-renal continuum.